ABC/123 Version X 1 Case Study Worksheet CCMH/522 Ver 272398
ABC/123 Version X 1 Case Study Worksheet CCMH/522 Version Universi
Answer the following questions for the assigned case study. Each response should be sufficient to answer the question appropriately (around 50–75 words each, when applicable). Think critically about your responses to each question. Do not respond with statements that indicate you are not in a position to prescribe or diagnose; this is practice to utilize your critical-thinking skills.
Paper For Above instruction
Primary presenting problems in the case
Kenny exhibits prominent symptoms including social withdrawal, disorganized speech, bizarre behavior, neglect of personal hygiene, and emotional detachment. He shows signs of hallucinations or delusional thinking, indicated by staring episodes and mumbling as if talking to someone, suggesting possible psychosis. His agitation, hostility, and sudden behavioral changes imply underlying severe mental health issues, likely affecting his daily functioning and social interactions.
Potential DSM-5 diagnosis
The symptomatology aligns with Schizophrenia, characterized by hallucinations, disorganized speech, social withdrawal, and negative symptoms like neglect of hygiene. Alternative or comorbid diagnoses might include Schizoaffective disorder or Bipolar Disorder with psychotic features, but current evidence most strongly suggests Schizophrenia based on the presentation.
Suggested medication, dosage, and timing
Ongoing antipsychotic treatment is recommended, such as Risperidone at a dose of 2 mg daily, preferably taken in the evening to mitigate sedative effects and optimize sleep. Dose titration should be based on response and tolerability, with regular follow-up to monitor efficacy and side effects.
Primary side effects to address
Possible side effects include weight gain, sedation, extrapyramidal symptoms such as tremors or rigidity, and metabolic changes like dyslipidemia or glucose intolerance. Addressing these involves weight management, monitoring metabolic parameters, and educating the client about early symptoms of movement disorders to prevent complications.
Hospitalization considerations and rationale
Hospitalization may be warranted if Kenny's safety is compromised due to severe agitation, suicidal ideations, or risk to others. Given the severity of his disorganized behavior and neglect, inpatient care could stabilize his condition, ensure medication adherence, and prevent harm during acute psychotic episodes.
Alternative treatments and medications
Psychosocial interventions such as individual therapy, family counseling, and social skills training are crucial. Pharmacologically, integrating atypical antipsychotics like Olanzapine or Clozapine might be considered if response to initial medication is inadequate, especially for refractory symptoms or side effect profiles.
Analysis of the case study
This case underscores the importance of comprehensive assessment in psychotic disorders. Early intervention with medication and therapy can significantly impact prognosis. Addressing environmental factors, family support, and monitoring for medication side effects are vital for effective management. Multidisciplinary approaches increase the chance of successful outcomes, emphasizing the importance of early diagnosis and tailored treatment plans.
References
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
- Berman, R. M., et al. (2014). The pharmacological management of schizophrenia. Journal of Clinical Psychiatry, 75(6), 601–610.
- Goff, D. C., & Weinberger, D. R. (2009). The neurodevelopmental hypothesis of schizophrenia: Updating the evidence. Biological Psychiatry, 65(10), 1220–1228.
- Keks, S., & Barnes, T. R. (2015). Management of schizophrenia: Antipsychotic pharmacotherapy. Australian & New Zealand Journal of Psychiatry, 49(10), 917–923.
- Leucht, S., et al. (2015). Oral versus long-acting injectable antipsychotics for relapse prevention in schizophrenia. Cochrane Database of Systematic Reviews, (4).
- Miyamoto, S., et al. (2012). Pharmacological treatment of schizophrenia: An update. Nature Reviews Drug Discovery, 11(9), 620–635.
- Weinberger, D. R., & Levitt, P. (2011). Neurodevelopmental origins of schizophrenia. Dialogues in Clinical Neuroscience, 13(3), 293–305.
- Lieberman, J. A., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209–1223.
- Correll, C. U., et al. (2014). Antipsychotic pharmacotherapy in schizophrenia: Advances and challenges. Expert Opinion on Pharmacotherapy, 15(4), 477–490.
- Mueser, K. T., & McGurk, S. R. (2004). Schizophrenia. The Lancet, 363(9426), 2063–2072.